Jazz Pharmaceuticals News

JAZZ has been the subject of a number of other recent research reports. Analysts at Auriga reiterated a "buy" rating on shares of Jazz Pharmaceuticals in a research note to investors on Wednesday, May 9th.

Overview -- Ireland-based Jazz Pharmaceuticals plc plans to use a new, $600 million credit facility to fund the pending $650 million acquisition of EUSA Pharma Inc.

Jazz Pharmaceuticals Inc. reported net income above Wall Street's expectations for the first quarter.

He had been a partner for more than six years at Latham & Watkins, where he began his career, and was most recently based in its Silicon Valley office.

A live webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

One biotech stock that is currently on its way back up is Dendreon . Dendreon is a growing player in the biotech industry with a 1.5 current ratio reported, although this number inspires less confidence than that of other biotech companies such as Jazz Pharmaceuticals , and Cell Therapeutics , with current ratios of 4.2 and 3.1, respectively.